Aloe emodin promotes mucosal healing by modifying the differentiation fate of enteroendocrine cells via regulating cellular free fatty acid sensitivity

Weilian Bao,Jiaren Lyu,Guize Feng,Linfeng Guo,Dian Zha,Keyuan You,Yang Liu,Haidong Li,Peng Du,Daofeng Chen,Xiaoyan Shen
DOI: https://doi.org/10.1016/j.apsb.2024.05.027
IF: 14.903
2024-06-02
Acta Pharmaceutica Sinica B
Abstract:The proper differentiation and reorganization of intestinal epithelial cell population plays a crucial role in mucosal regeneration post injury. Label retaining cells (LRCs) expressing SRY-box transcription factor 9 (SOX9) have been identified as key players in promoting epithelial repair by supplementing LGR5 + intestinal stem cells (ISCs). On the other hand, LRCs are also considered precursor cells for enteroendocrine cells (EECs) which exacerbate mucosal damage in inflammatory bowel disease (IBD). Factors determining LRC-EEC differentiation and the impact of intervening in LRC-EEC differentiation on IBD remain unclear. In this study, we investigated the effects of a natural anthraquinone called aloe emodin, derived from the Chinese herb rhubarb, on mucosal healing in IBD models. Our findings demonstrated that aloe emodin effectively interfered with the differentiation to EECs and preserved a higher number of SOX9 + LRCs, thus promoting mucosal healing. Furthermore, we discovered that aloe emodin acted as an antagonist of free fatty acid receptors (FFAR1), inhibiting the FFAR1-mediated G βγ /serine/threonine-protein kinase (AKT) pathway and promoting the translocation of forkhead box protein O1 (FOXO1) into the nucleus, which ultimately resulted in the intervention of differentiation fate. This research reveals the effect of free fatty acid accessibility on EEC differentiation and introduces a strategy for promoting mucosal healing in IBD by regulating the FFAR1/AKT/FOXO1 signaling pathway.
pharmacology & pharmacy
What problem does this paper attempt to address?